Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBI-833 in advanced solid tumors
NCT02310464Phase 1Completed
- Sponsor
- OBI Pharma
- Start
- Dec 2015
- Primary completion
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of OBI-833 in gastric cancer (GC), lung cancer, colorectal cancer (CRC) and 1 more (2 arms), sponsored by OBI Pharma. Primary endpoint: Treatment-emergent Adverse Events at 44 weeks. Started Dec 2015; status: completed.
02
Drugs
OBI-833
03
Conditions
gastric cancer (GC)lung cancercolorectal cancer (CRC)breast cancer
Beyond the preview
Go deeper on NCT02310464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02310464.